Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Jun;7(2):315-25.
doi: 10.1007/s12015-010-9202-x.

Immunological barriers to stem-cell based cardiac repair

Zaruhi Karabekian  1 , Nikki Gillum Posnack, Narine Sarvazyan
Affiliations
Review

Immunological barriers to stem-cell based cardiac repair

Zaruhi Karabekian et al. Stem Cell Rev Rep. 2011 Jun.

Abstract

Repair of damaged myocardium with pluripotent stem cell derived cardiomyocytes is becoming increasingly more feasible. Developments in stem cell research emphasize the need to address the foreseeable problem of immune rejection following transplantation. Pluripotent stem cell (PSC) derived cardiomyocytes have unique immune characteristics, some of which are not advantageous for transplantation. Here we review the possible mechanisms of PSC-derived cardiomyocytes rejection, summarize the current knowledge pertaining to immunogenicity of such cells and describe the existing controversies. Myocardial graft rejection can be reduced by modifying PSCs prior to their differentiation into cardiomyocytes. Overall, this approach facilitates the development of universal donor stem cells suitable for the regeneration of many different tissue types.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Schematic representation of direct and indirect recognition of donor antigens to the recipient T cells
Fig. 2
Fig. 2
Cartoon illustrating trends of MHC-I expression and NK susceptibility observed upon differentiation of pluripotent stem cells
Fig. 3
Fig. 3
Top Panel: Immunostaining of mouse ESC-derived cardiomyocytes (LONZA, catalog number XCAC-1010N). Bottom panel: ESC-derived cardiomyocytes were pretreated with interferon-gamma to elevate the baseline expression of MHC-I. RNA inhibition successfully blocked beta-2 microglubulin expression, thus preventing formation of functional MHC-I molecules
See this image and copyright information in PMC

References

    1. Zak R. Development and proliferative capacity of cardiac muscle cells. Circulation Research. 1974;35(suppl II):17–26. - PubMed
    1. Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science. 2009;324:98–102. - PMC - PubMed
    1. Pasumarthi KB, Field LJ. Cardiomyocyte cell cycle regulation. Circulation Research. 2002;90:1044–1054. - PubMed
    1. Hodgson DM, Behfar A, Zingman LV, et al. Stable benefit of embryonic stem cell therapy in myocardial infarction. American Journal of Physiology. Heart and Circulatory Physiology. 2004;287:H471–H479. - PubMed
    1. Caspi O, Huber I, Kehat I, et al. Transplantation of human embryonic stem cell-derived cardiomyocytes improves myocardial performance in infarcted rat hearts. Journal of the American College of Cardiology. 2007;50:1884–1893. - PubMed

Publication types

MeSH terms

Substances